Skip to content
Search AI Powered

Latest Stories

This New Agreement Between 23andMe and GlaxoSmithKline Pharmaceuticals Is Causing Major Concern Among Privacy Advocates

This New Agreement Between 23andMe and GlaxoSmithKline Pharmaceuticals Is Causing Major Concern Among Privacy Advocates

The future that TED Talks have long promised is one step closer to reality.

The future that TED Talkshavelongpromised is one step closer to reality, thanks to a new deal between pharmaceutical giant GlaxoSmithKline (GSK) and home DNA-testing kit service 23andMe.

The four-year agreement will grant GSK exclusive access to 23andMe’s database of genetic information, with the goal of developing new, targeted drugs and therapies. This isn’t the first time that 23andMe has offered its customers’ data to another organization for research, but those partnerships have previously been transparent. What does this new deal mean for genetic privacy and who will benefit from the partnership?


To privacy advocates,there’s little more alarming than the sale of genetic information. The data could be used by insurance companies to identify certain genetic markers as high-risk, leading to increased premiumseven decades after the test is performed. Law enforcement could subpoena the data from 23andMe (or any other genetic testing company) without informing the customers and without their consent. Thelaw surrounding questions of genetic privacy and ownership are in their infancy. And no genetic testing company canensure that your genetic information remains private.

But in this case, the most serious issue seems to be profit. 23andMe’s estimated 5 million customers can choose to opt out of having their DNA used in research. Those who don’t opt out have essentially donated their genome to science. But that munificence is one-sided: whatever drugs or treatments are developed using the customers’ genetic information will be sold by GSK or 23andMe for profit.

And there’s certainly profit to be made. Separate from this deal, GSK has invested $300 million in 23andMe. It’s a relative bargain for GSK, because 23andMe’s database is up to 10 times larger than other available databases, and its customers have already paid for partial sequencing — typically a major expense.

For its part, GSK is confident that the partnership will produce effective treatments, which will benefit patients across the world. To begin, they’re focusing on treatments for Parkinson’s disease based on a gene called LRRK2 that is mutated in some Parkinson’s patients.

“When you get a genetically validated target and you pursue it, it’s twice as likely to end up being a medicine,” said GSK chief science officer Hal Barron.

Previously, 23andMe had been carrying out some genetic research itself, in partnership with the National Institutes of Health (NIH)  and University of California, Los Angeles and University of Southern California.In those cases, customers could see a clear benefit in allowing research to be carried out on their genome. Just by allowing the company to use the material that the customer had already given, they felt like part of a larger solution.

“It’s one thing for NIH to ask people to donate their genome sequences for the higher good,” Peter Pitts, president of the Center for Medicine in the Public Interest, told NBC News. “But when two for-profit companies enter into an agreement where the jewel in the crown is your gene sequence and you are actually paying for the privilege of participating, I think that’s upside-down.”

More from News

Bill Murray
@anthony_anderson5/TikTok

Bill Murray Snaps At Pushy Fan For Trying To Take Unwanted Photo At Movie Theater In Viral Video

Bill Murray wasn’t in the mood for surprises at a recent movie screening—especially not from an overzealous fan who got a little too close for comfort.

The Ghostbusters star, 73, was at AMC Lincoln Square 13 in New York City for a Q&A session tied to his new film The Friend when things got tense.

Keep ReadingShow less
JK Rowling Slammed After She Adds Asexual People To Her Growing List Of LGBTQ+ Targets
Mike Marsland/WireImage

JK Rowling Slammed After She Adds Asexual People To Her Growing List Of LGBTQ+ Targets

Harry Potter author JK Rowling must be growing bored with transphobia because now she's using her worldwide platform to whine about asexuals.

Sunday, April 6 was International Asexuality Day, and of course Rowling couldn't possibly just let the day go by.

Keep ReadingShow less
Perry Greene from TikTok video; Greene apologizing
Fox 5 Atlanta

MTG's Ex-Husband Apologizes After He's Caught On Video Verbally Accosting Muslim Women

Far right Representative Marjorie Taylor Greene's ex-husband publicly apologized for an incident in which he was caught on camera harassing three Muslim women who were praying in a mall parking lot just north of Georgia.

Video filmed on March 31 showed Perry Greene leaning out of his Tesla Cybertruck and heckling the women, telling them they're "worshiping a false god because y'all are pieces of sh*t" and repeatedly telling them to "go back to your country."

Keep ReadingShow less
Ted Cruz; Kelvin Sampson
Alex Wroblewski/AFP via Getty Images; Alex Slitz/Getty Images

Houston Fans Livid After Ted Cruz 'Curse' Strikes Again At NCAA Basketball Championship

In 2013, 2016 and 2021, Texas Republican Senator Ted Cruz was labeled the most hated man in Congress—by members of his own party. In 2023, Florida Republican Representative Matt Gaetz replaced him as the "most hated."

In a 2016 CNN interview, South Carolina Republican Senator Lindsey Graham said:

Keep ReadingShow less
Harriet Tubman
Library of Congress/Getty Images

National Parks Website Restores Harriet Tubman Photo To 'Underground Railroad' Page After Backlash

Following significant backlash, the National Park Service restored a previously-erased photo of Harriet Tubman from a webpage dedicated to the history of the Underground Railroad, in which she led 13 missions to rescue enslaved people.

A spokesperson said the changes were not authorized by the agency's leadership.

Keep ReadingShow less